Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02SAC
|
|||
| Drug Name |
Anti-CD123 CAR-T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [1] | |
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | ||
| Company |
Hebei Senlang Biotechnology Inc., Ltd.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 3 receptor alpha (IL3RA) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Apoptosis | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL3 Signaling Pathway | ||||
| Pathway Interaction Database | IL3-mediated signaling events | |||
| Reactome | GPVI-mediated activation cascade | |||
| G beta:gamma signalling through PI3Kgamma | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| RAF/MAP kinase cascade | ||||
| Interleukin receptor SHC signaling | ||||
| WikiPathways | IL-3 Signaling Pathway | |||
| Interleukin-2 signaling | ||||
| Interleukin-3, 5 and GM-CSF signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.